Advertisement
A vs CLPT
Which Stock Would AI Choose? Agilent Technologies (A) vs. ClearPoint Neuro (CLPT) Stock Comparison
Key Takeaways
- A (Agilent Technologies) is a mature, profitable life sciences and diagnostics giant with a ~$38 billion market cap, delivering consistent revenue growth and positive earnings per share (EPS).
- CLPT (ClearPoint Neuro) is a high-growth, pre-profit medical device company with a ~$423 million market cap, expanding its neurosurgery navigation platform and riding momentum from gene therapy partnerships.
- Agilent offers stability, a dividend yield of approximately 0.8%, and a price-to-earnings (P/E) ratio near 27, while ClearPoint Neuro remains unprofitable with a negative net margin above 70% but carries triple-digit revenue growth potential.
- ClearPoint Neuro's stock has experienced significantly higher volatility, with a 52-week range spanning roughly $8 to $30, compared to Agilent's more contained range of approximately $108 to $160.
- Analysts rate Agilent a consensus "Moderate Buy" with an average price target near $159, while ClearPoint Neuro draws a "Strong Buy" from three covering analysts with a $28.33 average target, though Weiss Ratings assigns it a "Sell" rating, highlighting the polarized sentiment.
- The two companies operate in fundamentally different risk-reward profiles: Agilent represents established value with AI-enhanced growth catalysts, while ClearPoint Neuro embodies speculative innovation tied to the emerging field of cell and gene therapy delivery.
Introduction
Comparing A (Agilent Technologies) and CLPT (ClearPoint Neuro) may seem unusual at first glance — one is a $38 billion analytical instruments and diagnostics powerhouse, and the other is a $423 million niche neurosurgical device company. Yet both operate within the broader healthcare and life sciences ecosystem, and each appeals to a distinct type of investor. Agilent draws those seeking dependable earnings, modest dividends, and measured innovation, while ClearPoint Neuro attracts traders and growth-oriented investors willing to accept higher risk for exposure to the fast-evolving field of MRI-guided neurosurgery and gene therapy delivery. This stock comparison explores how these two companies differ across business models, recent performance, risk factors, and market positioning, offering a balanced view for anyone evaluating relative performance in the current market environment.
A Overview and Recent Performance
Agilent Technologies is a global leader in laboratory instruments, consumables, software, and services for the life sciences, diagnostics, and applied chemical markets. Spun off from Hewlett-Packard in 1999, the company has built a durable franchise centered on chromatography, mass spectrometry, and laboratory automation. In recent weeks, Agilent has demonstrated strengthening fundamentals: its fiscal second-quarter 2026 results surpassed Wall Street expectations, with EPS of $1.49 versus the $1.41 consensus estimate and revenue of $1.83 billion, representing 10% year-over-year growth. The company also raised its full-year fiscal 2026 EPS guidance to a range of $6.00 to $6.10.
Price behavior in recent months reflects a stock recovering from early-2026 weakness. After dipping toward its 52-week low near $108 earlier this year, A shares have rebounded above $130, supported by several catalysts: FDA approval of its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for Bristol Myers Squibb's OPDIVO immunotherapy, the launch of the AI-powered xCELLigence RTCA eSight AI module for automated live-cell imaging, and the completion of the Biocare Medical acquisition in late June. These developments underscore Agilent's strategic push into higher-margin consumables, AI-enabled laboratory software, and oncology diagnostics — all aimed at strengthening recurring revenue streams.
CLPT Overview and Recent Performance
ClearPoint Neuro is a medical technology company specializing in MRI-guided platforms for minimally invasive neurosurgical procedures. Its flagship ClearPoint Neuro Navigation System — which has FDA clearance and CE marking — enables surgeons to perform precise intracranial interventions with real-time imaging feedback. The company also partners with pharmaceutical and biotech firms to support direct central nervous system delivery of gene and cell therapies in clinical trials. In recent quarters, ClearPoint Neuro has recorded accelerating revenue growth: the first quarter of 2026 brought record revenue of $12.1 million, a 43% year-over-year increase, driven by organic expansion and contributions from the IRRAS acquisition, which added neurocritical care products to the portfolio.
Despite this top-line momentum, profitability remains elusive. The company posted a Q1 2026 net loss with a negative net margin exceeding 70% and negative return on equity (ROE). Stock performance has been notably volatile: CLPT shares have traded between roughly $8 and $30 over the trailing 52 weeks, with sharp swings driven by clinical news flow — most notably the positive Phase 2 results from partner uniQure's AMT-130 gene therapy for Huntington's disease, which validated ClearPoint Neuro's SmartFlow Cannula system as a critical delivery tool. The company has guided for 2026 revenue of $52 to $56 million, implying continued double-digit growth, though the upcoming Q2 2026 earnings report on August 3 will test whether execution keeps pace with expectations.
Trending AI Robots
For traders seeking a data-driven edge in comparing stocks like A and CLPT, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving market conditions. Tickeron hosts hundreds of AI trading bots that collectively cover thousands of tickers, but only those demonstrating the strongest statistical alignment with current market dynamics earn a place in this featured section. These bots span diverse trading styles — from short-term momentum strategies to longer-duration trend-following approaches — and each comes with its own track record, risk parameters, and ticker focus. Performance metrics among featured bots can vary widely, with some historically generating annualized returns in the double-digit range through disciplined signal execution. Whether your interest lies in the stability of large-cap life sciences or the volatility of emerging medical device names, the Trending AI Robots section provides a practical starting point for identifying automated strategies calibrated to the current environment. Explore the Trending AI Robots to see which strategies align with your market outlook.
Head-to-Head Comparison
The contrast between Agilent Technologies and ClearPoint Neuro is sharp across nearly every dimension. In terms of business model, Agilent benefits from a diversified, global installed base of laboratory instruments paired with recurring consumables and service revenue — a "razor-and-blade" dynamic that supports predictable cash flows. ClearPoint Neuro, by contrast, relies on a concentrated set of neurosurgery navigation products and consumables, supplemented by preclinical development service contracts with biopharma partners. Its growth path is tightly coupled to the clinical and commercial success of gene and cell therapy programs, creating significant upside potential but also concentrated risk.
On financial stability, Agilent holds a commanding advantage: net margin near 20%, ROE above 24%, a debt-to-equity ratio of just 0.43, and positive free cash flow exceeding $1 billion annually. ClearPoint Neuro remains cash-flow negative with a debt-to-equity ratio of approximately 2.63 and relies on its cash reserves — roughly $38 million as of late 2025 — to fund operations. Market sentiment diverges accordingly: Agilent commands a consensus "Moderate Buy" rating from 19 analysts with a $159 average price target, reflecting broad institutional confidence, while ClearPoint Neuro's three-analyst consensus sits at "Strong Buy" with a $28.33 target, though this bullish view coexists with a "Sell" rating from Weiss Ratings.
Sector exposure further differentiates the two. Agilent serves pharmaceutical, biotech, diagnostics, chemical, and academic end markets, cushioning it against weakness in any single vertical. ClearPoint Neuro's fortunes hinge disproportionately on the adoption of MRI-guided neurosurgery and the regulatory progress of partner-led gene therapy programs. For traders, this translates into markedly different volatility profiles: Agilent's beta of 1.25 indicates moderate sensitivity to broader market moves, while ClearPoint Neuro's 52-week price swings of over 260% from low to high reflect the stock's event-driven nature.
Tickeron AI Verdict
Based on observable factors — trend consistency, financial stability, earnings visibility, and catalyst quality — Tickeron's AI framework would likely favor Agilent Technologies in the current market environment for investors prioritizing risk-adjusted returns. Agilent's combination of consecutive earnings beats, expanding AI-enabled product lines, a growing diagnostics portfolio, and a well-supported dividend creates a comparatively stable trend foundation that algorithmic models tend to reward. ClearPoint Neuro's sharp revenue acceleration and gene-therapy-related optionality present genuine upside potential, but its lack of profitability, negative cash flow, and elevated volatility introduce uncertainty that can weigh on AI-driven trend assessments. That said, for risk-tolerant traders focused on momentum and thematic growth, CLPT may still register as a compelling candidate within certain short-term or event-driven strategies. The AI's preference ultimately depends on the objective function it is optimized for — stability and consistency favor Agilent, while speculative upside favors ClearPoint Neuro in specific tactical windows.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and CLPT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileCLPT’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- CLPT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while CLPT’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 3 bearish.
- CLPT’s TA Score: 4 bullish, 7 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.14% price change this week, while CLPT (@Medical/Nursing Services) price change was +5.81% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
Reported Earning Dates
A is expected to report earnings on Aug 26, 2026.
CLPT is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | CLPT | A / CLPT | |
| Capitalization | 39.1B | 448M | 8,728% |
| EBITDA | 1.96B | -22.24M | -8,824% |
| Gain YTD | 2.301 | 9.211 | 25% |
| P/E Ratio | 27.79 | N/A | - |
| Revenue | 7.23B | 40.6M | 17,813% |
| Total Cash | 1.81B | 35.6M | 5,076% |
| Total Debt | 3.36B | 63.6M | 5,275% |
A | CLPT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 99 | |
PRICE GROWTH RATING 1..100 | 26 | 46 | |
P/E GROWTH RATING 1..100 | 51 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for CLPT (53) in the null industry. This means that A’s stock grew somewhat faster than CLPT’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLPT (100) in the null industry. This means that A’s stock grew similarly to CLPT’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for CLPT (99) in the null industry. This means that A’s stock grew somewhat faster than CLPT’s over the last 12 months.
A's Price Growth Rating (26) in the Biotechnology industry is in the same range as CLPT (46) in the null industry. This means that A’s stock grew similarly to CLPT’s over the last 12 months.
A's P/E Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for CLPT (100) in the null industry. This means that A’s stock grew somewhat faster than CLPT’s over the last 12 months.
| A | CLPT | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 80% |
| Stochastic ODDS (%) | 4 days ago 62% | 4 days ago 75% |
| Momentum ODDS (%) | 4 days ago 64% | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 64% | 4 days ago 80% |
| TrendWeek ODDS (%) | 4 days ago 64% | 4 days ago 77% |
| TrendMonth ODDS (%) | 4 days ago 57% | 4 days ago 85% |
| Advances ODDS (%) | 12 days ago 60% | 4 days ago 78% |
| Declines ODDS (%) | 4 days ago 64% | 6 days ago 85% |
| BollingerBands ODDS (%) | 4 days ago 68% | 4 days ago 71% |
| Aroon ODDS (%) | 4 days ago 60% | 4 days ago 85% |
Advertisement
CLPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | +2.47% | ||
| ICUI - CLPT | 57% Loosely correlated | +0.08% | ||
| ISRG - CLPT | 46% Loosely correlated | +0.10% | ||
| A - CLPT | 45% Loosely correlated | -0.25% | ||
| NVST - CLPT | 45% Loosely correlated | -1.69% | ||
| BLFS - CLPT | 44% Loosely correlated | -1.14% | ||
More | ||||